AUSBIOTECH 2010 NATIONAL CONFERENCE
SPEAKERS' PROFILE

Dr Axel Polack
General Partner
TVM Capital GmbH
Germany

Dr Polack came in December 2000, TVM Capital and General Partner at the Munich Life Science team. He currently represents the interests of TVM Capital on the boards of Noxxon Pharma AG (Berlin), Genetix Pharmaceuticals, Inc. (Cambridge , MS, USA) and invendo Medical (Kissingen) and in f -star (Vienna) and Probidrug AG (Hall). His scientific interests are: Molecular and Viral Oncology, Onkogenaktivierung , gene regulation and molecular immunology. Dr. Polack is a member of the Board of Trustees of the German Vaccine Research Foundation , Hannover.

Previously, he spent three years as Managing Director of Innovative Technologies GmbH, Neuherberg (ITN - today Ascenion GmbH). Ascenion is a subsidiary of the Life Science Foundation to promote science and research, and operates fully and exclusively the " Intellectual Property Asset Management " for scientific institutions of the Helmholtz community, such as the GSF - Research Center for Environment and Health in Munich. Prior to that, Dr. Polack was eight years deputy director of the GSF Institute for Clinical Molecular Biology. Dr. Polack graduated summa cum laude in medicine at the University of Freiburg (" Cloning and analysis of the nasopharyngeal carcinoma -derived Epstein -Barr virus isolates of M -ABA ... ") and his habilitation in 1993 in the field of virology (" Mechanism of c- myc activation in Burkitt 's lymphoma). His doctorate was awarded the Goedecke Research Award for basic medical research . Since 1984, as the responsible author or coauthor more than fifty works published in prestigious journals.